Skip to main content
. 2021 Mar 24;12:639095. doi: 10.3389/fphar.2021.639095

FIGURE 4.

FIGURE 4

Cilengitide inhibits proliferation of human NSCLC A549 cells. (A) Chemical structure of cilengitide. (B) IMR90, (C) CPAE and (D) A549 cells were treated with cilengitide for 24–72 h. After incubation, cell viability was measured by the CCK-8 assay. Experiments were performed in triplicate. Data represent mean ± SD. *p < 0.05, **p < 0.01 vs. untreated control.